TKPHF Earnings
Takeda Pharmaceutical Company Limited
1W: +3.1%
1M: +13.2%
3M: +17.8%
YTD: +33.5%
1Y: +41.6%
3Y: +49.0%
5Y: +73.0%
$41.15
-0.07 (-0.17%)
Weekly Expected Move ±8.1%
$35
$38
$41
$45
$48
Credit Risk of going bust: lower than 78% of companies Debt: 32.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.99 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $31.29B against a stock market value of $64.51B.
Distance to default 9.14 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $17.29B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Last Earnings
2026-07-30
EPS
¥0.44 (US$0.00)
▲ Beat +31.8%
Revenue
¥7.5B ($47M)
▲ Beat +6.1%
EPS Beat Streak: 4 quarters
Next Earnings
2026-10-29
EPS Estimate
¥44.53 (US$0.28)
Range: ¥44.28 - ¥45.37
Revenue Estimate
¥1.23T ($7.8B)
1 analysts
1 USD = 157.97 JPY
Estimate vs Actual
Earnings Surprise History
11/19
EPS Beats
15/19
Revenue Beats
58%
EPS Beat Rate
79%
Rev Beat Rate
Wall Street Forward Estimates
Quarterly
Annual
Estimate Revisions
Recent Revisions
| Date | Period | Fiscal Date | EPS Old | EPS New | Change | Rev Old | Rev New |
|---|---|---|---|---|---|---|---|
| 2026-10-26 | quarter | 2027-12-30 | ¥132.10 | ¥132.10 | — | ¥1,198,395,171,644 | ¥1,208,631,384,752 |
| 2026-10-26 | annual | 2027-03-31 | ¥124.23 | ¥125.29 | ▲ 1.06 | ¥4,691,900,141,540 | ¥4,731,976,479,352 |
| 2026-10-26 | annual | 2030-03-31 | ¥281.82 | ¥284.23 | ▲ 2.41 | ¥5,245,978,561,255 | ¥5,290,787,615,717 |
| 2026-10-26 | annual | 2031-03-31 | ¥329.53 | ¥332.35 | ▲ 2.82 | ¥5,313,431,718,492 | ¥5,358,816,930,892 |
| 2026-10-26 | quarter | 2028-06-30 | ¥73.26 | ¥73.89 | ▲ 0.63 | ¥1,156,416,358,292 | ¥1,166,294,005,135 |
| 2026-10-26 | quarter | 2027-03-30 | ¥-14.38 | ¥-14.51 | ▼ 0.13 | ¥1,117,513,628,444 | ¥1,127,058,983,702 |
| 2026-10-26 | quarter | 2027-09-30 | ¥142.11 | ¥142.11 | — | ¥1,167,410,809,408 | ¥1,177,382,366,464 |
| 2026-10-26 | quarter | 2027-06-30 | ¥68.57 | ¥69.15 | ▲ 0.58 | ¥1,166,911,061,630 | ¥1,176,878,350,040 |
| 2026-10-26 | annual | 2028-03-31 | ¥199.11 | ¥200.81 | ▲ 1.70 | ¥4,796,492,021,042 | ¥4,837,461,740,931 |
| 2026-10-26 | annual | 2029-03-31 | ¥244.01 | ¥246.10 | ▲ 2.09 | ¥4,947,451,643,720 | ¥4,989,710,800,436 |
| 2026-10-26 | quarter | 2028-03-30 | ¥102.08 | ¥102.08 | — | ¥1,153,417,871,624 | ¥1,163,269,906,592 |
| 2026-10-26 | quarter | 2026-12-30 | ¥44.15 | ¥44.53 | ▲ 0.38 | ¥1,218,910,048,481 | ¥1,229,321,491,477 |
| 2026-10-23 | annual | 2030-03-31 | ¥281.73 | ¥281.82 | ▲ 0.09 | ¥5,236,428,289,369 | ¥5,245,978,561,255 |
| 2026-10-23 | quarter | 2026-12-30 | ¥44.14 | ¥44.15 | ▲ 0.01 | ¥1,218,524,439,481 | ¥1,218,910,048,481 |
| 2026-10-23 | quarter | 2027-03-30 | ¥-14.38 | ¥-14.38 | — | ¥1,117,160,096,768 | ¥1,117,513,628,444 |
Earnings Call Transcripts
No transcripts available.